Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Emactuzumab is a monoclonal antibody against the colony-stimulating factor-1 receptor and targets tumor-associated macrophages (TAMs). This study assessed the safety, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of emactuzumab, as monotherapy and in combination with paclitaxel,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2019-08, Vol.30 (8), p.1381-1392
Hauptverfasser:	Gomez-Roca, C.A., Italiano, A., Le Tourneau, C., Cassier, P.A., Toulmonde, M., D’Angelo, S.P., Campone, M., Weber, K.L., Loirat, D., Cannarile, M.A., Jegg, A.-M., Ries, C., Christen, R., Meneses-Lorente, G., Jacob, W., Klaman, I., Ooi, C.-H., Watson, C., Wonde, K., Reis, B., Michielin, F., Rüttinger, D., Delord, J.-P., Blay, J.-Y.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use CSF-1R Dose-Response Relationship, Drug emactuzumab Female Humans Macrophage Colony-Stimulating Factor - blood Macrophage Colony-Stimulating Factor - metabolism Macrophages - drug effects Macrophages - immunology Male Maximum Tolerated Dose Middle Aged Neoplasms - blood Neoplasms - drug therapy Neoplasms - immunology Neoplasms - pathology Original articles paclitaxel Paclitaxel - pharmacology Paclitaxel - therapeutic use Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - antagonists & inhibitors Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - metabolism Skin - cytology Skin - immunology Treatment Outcome tumor microenvironment tumor-associated macrophages Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!